University of Utah
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Utah sits in the top decile of US sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count).
University of Utah: 818 sponsored US clinical trials, 138 recruiting.
University of Utah sponsors 818 registered US clinical trials on ClinicalTrials.gov, 138 of them currently recruiting, and 492 completed. 45 of these trials are in Phase 3-4 (later-stage) and 268 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Low Back Pain, with 8 trials.
Top-decile sponsor footprint
University of Utah ranks in the top decile of sponsors by registered trial count (#40 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
492 of 611 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
818 total, page 4 of 17
Couples Health Aging, Rhythms and Sleep Study
NCT05952284
Analysis of Medial Clear Space Widening in Weber B Ankle Fractures
NCT07028944
FAMS-T1D Self-Regulation and Social Support for T1D
NCT05820477
Impact of Non-Exudative Type 1 MNV on AMD Progression
NCT06125977
Promoting Resilience in Stroke Survivor-carepartner Dyads (ReStoreD)
NCT04845542
Personalized Ultrasonic Brain Stimulation for Depression
NCT05301036
App Delivered Brief Mindfulness Intervention for Surgical Patients
NCT05433389
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04754191
Survival of the Insignia Stem in Total Hip Arthroplasty
NCT05313321
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994
Straw Phonation Exercise Program for Pitch Extension
NCT05357222
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT05139368
Hematoma Block Versus Bier Block for Closed Fracture Reduction
NCT05086224
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
NCT04922736
Assessing Adolescent Use of Nexplanon Over Time
NCT04889079
Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures
NCT05019638
Refinement of Suicide Risk Management Intervention
NCT04888845
Sleep Technology Intervention to Target Cardiometabolic Health
NCT04766424
KidneyCare Cohort Study (KCC-S)
NCT06898632
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
NCT04409639
Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making
NCT04437069
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
NCT05736523
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT04109729
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
NCT04141644
Intracept Intraosseous Basivertebral Nerve Ablation
NCT05660512
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
NCT04163432
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
NCT04380311
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT03796767
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
NCT04106856
Role of Metformin on Muscle Health of Older Adults
NCT03107884
Neural and Antidepressant Effects of Propofol
NCT03684447
Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures
NCT05037812
Family Planning Elevated: Initiative Evaluation
NCT03877757
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT03825289
Detecting Post-surgical Respiratory Compromise and Prompting Patients to Self-rescue: An Early Feasibility Study
NCT02962557
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
NCT03171025
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
NCT03542409
On-Demand Oxygen Delivery System Study
NCT02962570
Quick Start of Highly Effective Contraception
NCT02076217
Memantine for Enhanced Stroke Recovery
NCT02144584
Inflammatory Response Following Intraarticular Fracture
NCT01514643
Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells
NCT01409954
At-Home Paracentesis for Women With Cancer-Related Malignant Ascites (Paracentesis)
NCT07490626
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
NCT07521046
Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)
NCT07599943
High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study
NCT07612345
Brief Postoperative Pain Management Intervention: Meaning Making Amendment
NCT07676500
Partnership to Reduce Obesity in Community Health Center Patients (SMARTLife Utah)
NCT07582016
LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)
NCT07620301
SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care
NCT07410689
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 145 |
| Phase 2 | 123 |
| Phase 3 | 18 |
| Phase 4 | 27 |
Therapeutic Areas
What is open in the University of Utah pipeline
138 recruiting of 818 indexed (17% open); 492 completed (60%).
Phase mix: 45 late (III/IV) vs 268 early (I/II) (early-phase heavy).
Top condition: Low Back Pain (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Utah: open-pipeline peers nationwide
Peers matched on 818 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
University of Utah sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 818 trials (± recruiting share)
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
Sponsors near 17% open enrollment (± trial volume)
- University of Hawaii · 17% recruiting · 77 trials
- Penn State University · 17% recruiting · 219 trials
- AdventHealth · 17% recruiting · 95 trials
- CSL Behring · 17% recruiting · 71 trials
Related
What to do with this University of Utah page
818 registered trials is a research-attention snapshot, not an endorsement of University of Utah or any single study.
- 138 of University of Utah's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Low Back Pain is the condition University of Utah studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Low Back Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Utah pipeline card: 818 registered trials from official public datasets.Report a data error.